Free shipping on all orders over $ 500
| Cat.No. | Name | Information |
|---|---|---|
| M2562 | ZCL278 | ZCL278 is a selective Cdc42 GTPase inhibitor with Kd of 11.4 μM. |
| M6282 | NSC 23766 | NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related targets, Cdc42 or RhoA. |
| M9356 | AMG-510 (Sotorasib) | AMG-510 (Sotorasib) is a potent KRAS G12C covalent inhibitor. |
| M9428 | MRTX849 (Adagrasib) | MRTX849 (Adagrasib) is a potent, highly selective, oral available KRAS G12C inhibitor. |
| M21533 | BI-0474 | BI-0474 is a covalent KRASG12C inhibitor. The IC50 value for GDP-KRAS::SOS1 protein-protein interaction was 7.0 nM. BI-0474 also showed better antitumor activity in non-small cell lung cancer xenograft models. |
| M21503 | MRTX849 acid | MRTX849 acid can be used to synthesize PROTAC LC-2. LC-2 is a potent, first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC50, between 0.25 and 0.76 μM). |
| M21369 | BDP9066 | BDP9066 is a potent and selective MRCK inhibitor, reducing substrate phosphorylation. |
| M21220 | ASP2453 | ASP2453 is a potent, selective and covalent inhibitor of KRAS G12C. ASP2453 inhibits Son of Sevenless (SOS)-mediated interactions between KRAS G12C and Raf with an IC50 value of 40 nM. |
| M21080 | AZD4625 | AZD4625 is a highly potent, selective, covalent and metabotropic inhibitor of the mutant GTPase KRASG12C. AZD4625 has high oral bioavailability. It is being developed to study advanced solid malignancies. |
| M20741 | Antineoplaston A10 | Antineoplaston A10 is a naturally occurring substance in the human body that that can be potentially used for the treatment of glioma, lymphoma, astrocytoma and breast cancer. The main ingredient active of antineoplaston A10 (Phenylacetylglutamine, PG) inhibits RAS and promotes apoptosis. |
| M20725 | MCP110 | MCP110 is an inhibitor of Ras/Raf-1 interaction. MCP110 disrupts the interaction of activated Ras with Raf and is potential for the treatment of human tumors. |
| M20708 | K-Ras-IN-1 | K-Ras-IN-1 inhibits K-Ras by binding to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure. |
| M20013 | MRTX0902 | MRTX0902 is an oral brain penetrating SOS1:KRAS protein-protein interaction inhibitor. |
| M14058 | Y16 | Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. |
| M14057 | RAS inhibitor Abd-7 | RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. |
| M14056 | PHT-7.3 | PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). |
| M14055 | Pan-RAS-IN-1 | Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors. |
| M14054 | MRTX-1257 | MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. |
| M14053 | Deltarasin hydrochloride | Deltarasin hydrochloride is an inhibitor of KRAS-PDEδinteraction with Kd of 38 nM for binding to purified PDEδ. |
| M14052 | CCG-100602 | CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (MRTF-A/SRF) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF. |
| M14051 | 1A-116 | 1A-116 is a Rac1 inhibitor, with antitumoral and antimetastatic effects in several types of cancer, such as breast cancer. 1A-116 prevents Rac1-regulated processes involved in the primary tumorigenesis and metastastic processes . |
| M13363 | CCG-222740 | CCG-222740 is an inhibitor of the Rho/MRTF pathway. CCG-222740 is also an effective α -smooth muscle actin protein expression inhibitor. CCG-222740 effectively reduces skin fibrosis and prevents melanoma metastasis. |
| M11442 | GDC-6036 | Gdc-6036 (compound 17A) is an oral covalently mutated KRAS G12C inhibitor with IC50<0.01 μM against K-Ras G12C. The EC50 of GDC-6036 in K-Ras G12C-alkylated HCC1171 cells was 2 nM. |
| M11427 | RM-018 | RM-018 is an inhibitor of the active state of KRASG12C. Rm-018 retains the ability to bind and inhibit KRASG12C/Y96D. Rm-018 combines with GTP-bound to activate the [" RAS(ON) "] state of KRASG12C. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
